Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
about
Efficacy and Safety of Injectable Robenacoxib for the Treatment of Pain Associated With Soft Tissue Surgery in Dogs.Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs.Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial.Safety of oral robenacoxib in the cat.Robenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial.Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in catsSparing effect of robenacoxib on the minimum alveolar concentration for blunting adrenergic response (MAC-BAR) of sevoflurane in dogs.DJD-associated pain in cats: what can we do to promote patient comfort?Osteoarthritis in the cat: 2. how should it be managed and treated?Feline hip dysplasia: A challenge to recognise and treat.Safety evaluation of the interchangeable use of robenacoxib (Onsior™) tablets and solution for injection in dogs.Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrationsRobenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapyInfluence of sevoflurane anesthesia with mechanical ventilation and fluid-therapy on distribution of subcutaneously administered robenacoxib in dogs
P2860
Q33698477-9330A71A-A754-4935-98EC-8F94F21D3148Q33836650-40F55B52-8922-46EE-A2C1-6B212E37689AQ34628373-EBBE2D19-2080-408C-B36C-83C1946B656CQ34630876-76DE0431-D552-48E0-82EA-B52F901B21C8Q34702739-29DAE4DA-1C6B-43EB-8D23-0B5F6B0947A9Q36060543-E28C989D-38C9-4D8F-B44C-7B20F001C296Q37692642-56127ECE-2806-43EC-B401-72C0C42AD022Q37701031-22E2637C-E35E-41A3-9C0D-F4B3DCA2645CQ37976032-D75C125C-753A-4407-8F2A-FD62FAD1E149Q38758657-84C44AB5-29BD-47EF-86A1-371D5AD61B80Q47142226-229B2080-90BE-4D38-8EED-7B53D069E865Q58770742-7FC2BF9F-ED2E-4481-8E88-5A8003499504Q58777712-409AF012-9FC5-4E92-AEC3-3B2E6AF49928Q58800798-7C7B2D08-ECE7-4CE3-95BC-82D91797C9DB
P2860
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
@ast
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
@en
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
@nl
type
label
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
@ast
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
@en
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
@nl
prefLabel
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
@ast
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
@en
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
@nl
P2093
P1476
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
@en
P2093
E F Kimble
P J Marshall
P L Toutain
R Fujimoto
P2860
P356
10.1111/J.1365-2885.2008.00962.X
P50
P577
2009-02-01T00:00:00Z